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DNA methylation in the IL-1β promoter in 3/5 patients. Further
work concentrated on this gene. Bisulﬁte modiﬁcation suggested
that the CpG sites at -290bp and - 247bp were important for
the epigenetic regulation of IL-1β, and the site at -290bp was
selected for quantiﬁcation of DNA methylation. We then deter-
mined which experimental conditions resulted in the greatest
loss of DNA methylation and whether this paralleled the in-
crease in mRNA expression. Culture with the de-methylating
factor 5-aza-dC halved DNA methylation, which resulted in 4-
8 fold increases in IL-1β expression compared with cultured
controls. This demonstrated that DNA de-methylation per se in-
creased gene expression. However, this was not the only factor
involved, since far greater effects were seen with the inﬂamma-
tory cytokines: IL-1β reduced methylation to ∼15%, cresulting in
50-100 fold increases in gene expression. The greatest effect
was seen with TNF-α/OSM, which abolished DNA methylation
almost completely and caused IL-1β expression to increase 500-
1000 fold. The cytokine-induced expression was translated into
protein. Unlike IL-1β, TNF-α expression was not susceptible to
auto-induction or epigenetic control.
Conclusions: A system has been developed in which loss of
DNA methylation in combination with 100-1000 fold increases in
gene expression can be induced experimentally - a crucial pre-
requisite for mechanistic studies. Moreover, we demonstrated for
the ﬁrst time that inﬂammatory cytokines can cause loss of DNA
methylation in addition to all other known effects, and that IL-1β
(but not TNF-α) induces its own expression.
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Purpose: Our previous work revealed differential roles for the
NF-κB activating kinases in controlling the progression towards
terminal differentiation of primary osteoarthritic chondrocytes.
Here we elaborate some of the multiple steps whereby IKKα
controls the terminal chondrogenic differentiation program.
Methods: Primary chondrocytes were derived from 15 Os-
teoarthritis (OA) patients undergoing joint arthroplasty. IKKα or
IKKβ shRNAs were stably expressed by pSuper retroviral trans-
duction of IKKα or IKKβ speciﬁc shOligos followed by selection
of puromycin resistant cells and KD efﬁciencies were veriﬁed by
immunoblotting. High density monolayer and micromass cultures
under mineralizing conditions were selected to investigate the
mechanisms whereby the IKKs control chondrocyte terminal dif-
ferentiation. Runx2 was evaluated by both REAL TIME PCR in 1
week old micromasses and by immunohistochemistry in 3 week
old micromasses and Sox9 expression in high density monolayer
cultures by immunoblotting. The effects of IKKα KD on type 2
collagen accumulation at the transcriptional or post-translational
levels were investigated in micromasses. ECM remodelling was
directly evaluated by staining for neoepitopes (Col2 3/4 C and
DIPEN and NITEGE). Moreover, IKKα expression was rescued
in IKKα KD chondrocytes with either a wild type or kinase-dead
IKKα(K44M) mutant to explore the connection between IKKα’s
effects on chondrogenesis and the NF-κB pathway.
Results: IKK KDs were at least 80% and generally greater than
90%. Both IKK KD were found associated with increased Col2
mRNA expression and also resulted in defective ECM remod-
elling as shown by IHC detection of neoepitopes. Silencing IKKβ
markedly increased sGAG accumulation, in conjunction with in-
creased Sox9 expression. However, IKKα ablation markedly en-
hanced collagen 2 deposition independently of Sox9 but instead
in association with a strong remodelling block in conjunction with
Runx2 suppression. In addition ablation of either IKKα or IKKβ
also inhibited Collagen X deposition thus providing additional
evidence, along with blocks in calcium deposition, that each IKK
(albeit via different mechanisms) is of central importance for
progression towards terminal differentiation.
Conclusions: We have uncovered an unexpected, pivotal role
for IKKα in the terminal chondrogenesis of primary osteoarthritic
human chondrocytes. IKKα controls the transition to the hyper-
trophic phase at multiple levels, while IKKβ appears to mimick
the effects of canonical NF-κB activation. Preliminary indications
of an IKKα rescue experiment suggest that its more profound ef-
fects could be independent of the NF-κB pathway. In conjunction
with the healthier status of IKKα KD chondrocytes, with respect
to their extensive ECM and high viability, our results support
the view that IKKα could be a novel therapeutic target for Os-
teoarthritis with its ablation causing a profound blockage towards
terminal differentiation.
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Purpose: While investigating the effects of sharp injury upon
inﬂammatory signalling pathways in articular cartilage, we found
that synovial ﬂuid strongly activated MAP kinases in cartilage
explants adapted to culture. We set out to identify the activator
and investigate its effects on chondrocyte function.
Methods: Cartilage from porcine metacarpophalangeal joints
was cultured in serum-free medium for 24h before treatment with
porcine synovial ﬂuid. Tissue extracts were analysed for MAPK
(ERK, p38 and JNK) and ATF-2 (a preferred JNK substrate)
activation by phospho-Western blotting. Culture medium sam-
ples were analysed for the presence of aggrecanase-generated
aggrecan fragments by using antibodies against the aggrecan
ARGS neoepitope. Porcine synovial ﬂuid was subjected to se-
quential chromatography (Resource Q, Resource S and Blue
Sepharose) and the MAPK activator was identiﬁed by mass-
spectrometry.
Results: The porcine synovial ﬂuid activator was identiﬁed as
apolipoprotein A-1 (APOA-1) the major component of high den-
sity lipoprotein (HDL) in tissue ﬂuids. Porcine APOA-1 puriﬁed
from synovial ﬂuid and commercially available human APOA-1
activated MAPKs and also induced aggrecan breakdown in cul-
tured cartilage. APOA-1 induced mRNA of ADAMTS-4 and -5
and MMP-13. APOA-1 differed from typical inﬂammatory medi-
ators that cause cartilage catabolism (IL-1, TNF, LPS), in that it
did not induce cyclooxygenase-2 (COX-2), a typical inﬂammatory
response gene.
Conclusions: APOA-1 in synovial ﬂuid causes MAPK activa-
tion and induces aggrecanases in cartilage. It appears to cause
a matrix-resorbing response without inducing inﬂammatory re-
sponse genes. APOA-1 (apparent Mr ∼120kD) may normally be
excluded from the cartilage matrix but is perhaps able to access
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the cut surface of explants. Alternatively, chondrocytes in cul-
tured tissue may acquire sensitivity to this ubiquitous component
of tissue ﬂuid. These possibilities are under investigation.
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Purpose: Decoy receptor 3 (DcR3), a newly identiﬁed member
of the TNF receptor (TNFR) superfamily, is a soluble receptor
binding to the TNF family including Fas-ligand (Fas-L), LIGHT,
and TL1A. DcR3 is mostly expressed in tumor cells and competi-
tively inhibits TNF binding to TNFR. In this study, we investigated
DcR3 expression and analyzed DcR3 function in osteoarthritis
(OA) cartilage.
Methods: Expressions of DcR3 in chondrocytes were measured
by RT-PCR and westernblotting. OA chondrocytes were incu-
bated with DcR3-Fc chimera protein (DcR3-Fc) before induction
of apoptosis. Apoptosis induced by Fas in OA chondrocytes were
detected with TUNEL staining and westernblotting of caspase 8
and poly (ADP-ribose) polymerase (PARP). Proliferation of chon-
drocytes were analysed by WST assay. After incubation with
DcR3-Fc, PD098059 or SB203580. Activation of extracellular-
signal regulated kinase (ERK), P38 mitogen-activated protein
kinase (P38MAPK) and c-jun N-terminal kinase (JNK) in chon-
drocytes were measured by westernblotting.
Results: DcR3 mRNA and protein were expressed in OA chon-
drocytes. RT-PCR and real-time PCR revealed that DcR3 mRNA
was expressed in all the individual samples of OA and normal
chondrocytes (Fig. 1a). Western blotting conﬁrmed that DcR3
protein was expressed in OA and normal chondrocytes (Fig. 1b).
DcR3 protein inhibited Fas-induced apoptosis in chondrocytes.
TUNEL positive apoptotic cells induced by Fas-L in chondrocytes
were signiﬁcantly decreased in a dose dependent manner when
chondrocytes were pre-incubated with DcR3-Fc protein (Fig.
2a). Cleavage of caspases were also signiﬁcantly decreased
(Fig. 2b).
DcR3 stimulates chondrocytes proliferation. Proliferation assay
revealed that the growth rates of chondrocytes were not signif-
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icantly increased by the treatments with 5000 ng/ml of IgG1 in
control medium. However, the growth rates of chondrocytes were
signiﬁcantly increased by the treatments with least 1000 ng/ml of
DcR3-Fc in control medium (Fig. 2c),
DcR3 stimulates the ERK signaling pathway. Western blotting
revealed that ERK signaling was activated by the treatment with
5000 ng/ml of DcR3-Fc for 10 min (Fig. 3) However, Neither P38
MAPK nor JNK signaling was not activated by the treatment with
5000 ng/ml of DcR3-Fc for up to 30 min (Fig. 3).
Suppression of ERK activity decreased chondrocytes prolifera-
tion introduced by DcR3.
Proliferation assay revealed that chondrocytes proliferation were
signiﬁcantly increased by the treatment with 5000 ng/ml of DcR3-
Fc.
chondrocytes proliferation were inhibited by the treatment with
5000 ng/ml of DcR3-Fc and PD098059 (Fig. 4a). Chondro-
cytes proliferation were increased by the treatment with 50µM of
SB203580, and proliferation were more increased by the treat-
ment with SB203580 and DcR3-Fc (Fig. 4a).
Western blotting conﬁrmed that the activation of ERK signaling
was inhibited by the treatment with 5000 ng/ml of DcR3-Fc and
PD 98059 (Fig. 4b).
Conclusions: Our results strongly suggest that DcR3 actually
protects OA chondrocytes from death via Fas-induced apoptosis
